NCT04554056已完成2 期
A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 586
- 试验地点
- 1
- 主要终点
- The primary objective of this study will be to evaluate the efficacy of MW05 pre-filled syringe as compared to PEG-rhG-CSF standard dosing (6 mg) in the first chemotherapy cycle.
研究概览
简要总结
In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy treatment. Three group were treated with MW05 300 μg/kg or MW05 500 μg/kg or PEG-rhG-CSF 100 μg/kg on the 3th day of each cycle randomized 1:1:1 .
The dose of the experimental drug MW05 in phase III were determined by independent data monitoring committee (IDMC) according to the efficacy and safety of phase II. Subjects were randomly divided into two groups 1:1 to received either MW05 or PEG-rhG-CSF(100 μg/kg) on the 3th day of each chemotherapy cycle.
详细描述
Study Stage: Phase II/III Study Population Female patients with breast cancer will be enrolled to receive at least 4 cycles of TC chemotherapy, that is: Docetaxel 75 mg/m2 and Cyclophosphamide 600 mg/m2.
Study Design: A multi-center, randomized, open-label, active-controlled phase II/III clinical trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •18～70 years old female(including threshold)
- •Diagnosed with breast cancer .
- •Weight≥45kg.
- •Patients planned to receive TC chemotherapy.
- •Estimated survival time ≥ 3 months, and could received at least 4 cycles chemotherapy treatment.
- •Have suitable organs and hematopoietic function
- •ECG examination is normal or abnormal has no clinical significance.
- •B-ultrasound examination of abdomen showed no obvious abnormality of spleen.
- •Willing to sign the informed consent form and able to comply with protocol requirements.
- •Non-menopausal or non-surgically sterilized female subjects, the blood pregnancy test results must be negative at the time of screening, and within at least 3 months from the signing of the informed consent form to the end of the last administration, consent to abstinence or the use of effective contraceptive methods.
排除标准
- •History of other malignant tumors (skin basal cell carcinoma, skin squamous cell carcinoma and / or carcinoma in situ after radical resection can be included in the group after being cured for more than 5 years)
- •Primary hematological diseases, including but not limited to myelodysplastic syndrome, aplastic anemia, sickle cell anemia and other hematological diseases that affect bone marrow hematopoiesis.
- •With known central nervous system metastasis or suspected central nervous system metastasis based on clinical manifestations.
- •With previous history of bone marrow transplantation and / or stem cell transplantation.
- •Currently uncontrolled infections or have received systematic anti-infective therapy within 72 hours before randomization.
- •Serious chronic diseases of important organs such as kidney and liver.
- •Severe heart disease, including but not limited to:history of congestive heart failure (New York College of Cardiology [NYHA] II or higher heart disease)Angina pectoris that needs to be treated with anti-angina pectoris drugsUncontrollable hypertension (systolic blood pressure ≥ 180 mmHg and / or diastolic blood pressure ≥ 100 mmHg)Arrhythmias requiring drug treatment
- •Severe diabetes (such as fundus disease or diabetic foot), or blood sugar is still not well controlled after active treatment.
- •Surgery within 2 weeks before chemotherapy or radiotherapy within 4 weeks (except for patients whose physical condition has recovered and can accept the relevant procedures of this study, as determined by the researchers)
- •Adverse reactions from previous treatments failed to recover to CTCAE v5.0 score ≤ 1 (except for alopecia and other toxic reactions that researchers believe do not affect the safety of this chemotherapy)
- •According to the researchers, there are serious risks to the safety of patients or concomitant diseases that affect the completion of the study.
- •Participated in clinical trials of any other drugs within 4 weeks.
- •Received the same efficacy drugs(such as PEG-rhG-CSF or rhG-CSF, etc.) are still in 5 half-lives or within 28 days (whichever is shorter).
- •With allergic disease or allergic constitution, and who have previously been allergic to any drug or its components in this trial.
- •Active hepatitis B (HBsAg positive and HBV-DNA copy number greater than the normal limit) and / or active hepatitis C (hepatitis C virus antibody positive and HCV-RNA copy number greater than the normal limit) and / or human immunodeficiency virus antibody positive and / or Treponema pallidum antibody.
- •Drug abuse. history or drug abusers
- •Pregnant or lactating women
- •Who have been judged by the researchers to be unsuitable for selection or who are not suitable for other reasons
研究组 & 干预措施
MW05 300μg/kg
Experimental
Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
干预措施: MW05 (Drug)
MW05 500μg/kg
Experimental
Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
干预措施: MW05 (Drug)
PEG-rhG-CSF
Active Comparator
Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
干预措施: PEG-rhG-CSF (Drug)
结局指标
主要结局
The primary objective of this study will be to evaluate the efficacy of MW05 pre-filled syringe as compared to PEG-rhG-CSF standard dosing (6 mg) in the first chemotherapy cycle.
时间窗: in cycle 1（each cycle is 21 days）
The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC \<0.5 x 109/L) observed in chemotherapy cycle 1.
次要结局
- The incidence of grade 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 0.5 × 109/L）(through study completion, in overall 4 cycles（each cycle is 21 days）)
- The incidence of grade 3 or 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）(through study completion, in overall 4 cycles（each cycle is 21 days）)
- The duration of grade 3 or 4 neutropenia In cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）(through study completion, in overall 4 cycles（each cycle is 21 days）)
- The duration of grade 4 neutropenia in cycle 2~4 assessed by ANC（ANC < 0.5 × 109/L）(in cycles 2-4, in overall 3 cycles（each cycle is 21 days）)
- Incidence of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)(through study completion, in overall 4 cycles（each cycle is 21 days）)
- The proportion of subjects rescued by short-acting G-CSF in cycle 1~4.(through study completion, in overall 4 cycles（each cycle is 21 days）)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomasSquamous Cell Carcinoma of Head and NeckNCT06557889Institut Claudius Regaud86
招募中
2 期
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaEsophageal CancerNCT06718205The First Affiliated Hospital of Zhengzhou University112
已完成
2 期
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung CancerNon-small Cell Lung CancerSquamous Cell CarcinomaNCT01631357Tianjin Medical University Cancer Institute and Hospital96
终止
2 期
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell TumorsGerm Cell TumorNCT03081923Fondazione IRCCS Istituto Nazionale dei Tumori, Milano36
Unknown
2 期
Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced MelanomaUntreated PatientsAdvanced MelanomaNCT00813449Simcere Pharmaceutical Co., Ltd140